Appointment of Shadow Lake Group for Business Development 2021-08-18 16:05 ET - News Release
NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Shadow Lake Group Inc. and its affiliate SLG Europe BV (“SLG”) as Business Development advisor.
“We are delighted to engage with Shadow Lake Group to expand our business development efforts,” said Deborah Rathjen, Ph.D., Bioasis’ Executive Chair. “The team at SLG will be able to leverage their previous knowledge of the xB3™ platform as well as their extensive transaction experience in neuroscience and oncology in the establishment of new and meaningful strategic partnerships for Bioasis.”
“The team at SLG is very excited to be working with Bioasis once again to support commercialization of this important and much needed BBB delivery platform,” said John Proffett, Managing Partner and Co-Founder of SLG. “We are impressed with the significant progress that the Bioasis team has made in both scientific and business development activities since our previous engagement, and we are looking forward to contributing to the future growth of the Company.”
About Shadow Lake Group Inc.
Shadow Lake Group and its affiliate SLG Europe BV (SLG) is a boutique life sciences transaction advisory firm with a global focus. SLG works with both private and public companies in all therapeutic areas and stages of development to help them achieve their business goals. SLG has offices in Toronto, Canada, Boca Raton, Florida, and Amsterdam, the Netherlands.
https://shadowlakegroup.com/